Myocardial salvage after myocardial infarction depends on early therapy

摘要

In a thought-provoking session on triple anti-platelet therapy in acute coronary syndromes, Prof Marco Valgimigli, Ferrara, Italy, argued that the effect of clopidogrel is negligible if given too late to ST-segment elevation myocardial infarction (STEMI) patients. 'Clopidogrel is not fully absorbed during STEMI. This impaired bio-availability of both the active and inactive metabolite,1 combined with late administration of clopidogrel, results in minimal anti-platelet inhibition. In fact, there is limited clinical evidence supporting the upstream use of clopidogrel', he said.